Johnson & Johnson (NYSE:JNJ) Stock Position Increased by Capital Advisors Inc. OK

Capital Advisors Inc. OK grew its position in Johnson & Johnson (NYSE:JNJ) by 2.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 82,301 shares of the company’s stock after buying an additional 1,986 shares during the period. Capital Advisors Inc. OK’s holdings in Johnson & Johnson were worth $12,144,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. lifted its holdings in Johnson & Johnson by 0.6% in the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after purchasing an additional 1,168,129 shares during the period. Geode Capital Management LLC lifted its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock worth $5,100,421,000 after acquiring an additional 572,077 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Johnson & Johnson by 10.8% in the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after acquiring an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after acquiring an additional 2,118,870 shares in the last quarter. Finally, Capital World Investors increased its stake in shares of Johnson & Johnson by 182.9% during the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after acquiring an additional 13,703,905 shares during the period. 67.44% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:JNJ traded up $0.54 during trading on Tuesday, reaching $148.89. 4,375,700 shares of the company traded hands, compared to its average volume of 8,477,668. The firm has a fifty day simple moving average of $149.29 and a 200 day simple moving average of $144.17. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The firm has a market cap of $390.58 billion, a P/E ratio of 21.77, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. During the same period last year, the company earned $2.58 earnings per share. Johnson & Johnson’s quarterly revenue was down 10.8% compared to the same quarter last year. As a group, research analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.71%. The ex-dividend date of this dividend was Monday, August 24th. Johnson & Johnson’s payout ratio is presently 46.54%.

JNJ has been the subject of a number of research reports. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $161.00 to $164.00 in a report on Monday, July 20th. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price target on the stock. in a research report on Tuesday, July 7th. Raymond James raised their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Finally, SVB Leerink reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $163.00.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the sale, the executive vice president now owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How do analysts define an oversold condition?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.